Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/1b Study of RMC-6291 Monotherapy in Advanced KRAS G12C Mutant Solid Tumors
TCTR20230412004Phase 1Terminated
- Sponsor
- Revolution Medicines
- Start
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of elironrasib in Nonhematologic neoplasms, sponsored by Revolution Medicines. Primary endpoints: Maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) and Safety and tolerability. Started Jan 2024; status: terminated.
02
Drugs
elironrasib
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on TCTR20230412004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20230412004.